{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T10:39:29Z","timestamp":1720175969853},"reference-count":39,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.3892\/or.2014.3249","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T03:16:04Z","timestamp":1402542964000},"page":"627-634","source":"Crossref","is-referenced-by-count":6,"title":["A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells"],"prefix":"10.3892","volume":"32","author":[{"given":"OU","family":"HUANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZUOQUAN","family":"XIE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEILI","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YING","family":"LOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YAN","family":"MAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HONGCHUN","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MIN","family":"JIANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KUNWEI","family":"SHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"key":"key20180107210043_b1-or-32-02-0627","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key20180107210043_b2-or-32-02-0627","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/djt043","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in the Women\u2019s Health Initiative Observational Study","volume":"105","author":"Chlebowski","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"key20180107210043_b3-or-32-02-0627","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1071884","article-title":"Connections and regulation of the human estrogen receptor","volume":"296","author":"McDonnell","year":"2002","journal-title":"Science"},{"key":"key20180107210043_b4-or-32-02-0627","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mds238","article-title":"A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative","volume":"24","author":"Brouckaert","year":"2013","journal-title":"Ann Oncol"},{"key":"key20180107210043_b5-or-32-02-0627","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2013.12.011","article-title":"Use of SERMs for treatment in postmenopausal women","volume":"142C","author":"Pinkerton","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20180107210043_b6-or-32-02-0627","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrclinonc.2012.21","article-title":"Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer","volume":"9","author":"Goncalves","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180107210043_b7-or-32-02-0627","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"key20180107210043_b8-or-32-02-0627","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40265-013-0030-6","article-title":"Drugs in development for relapsing multiple sclerosis","volume":"73","author":"Ali","year":"2013","journal-title":"Drugs"},{"key":"key20180107210043_b9-or-32-02-0627","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/CPJ.0b013e318296f299","article-title":"Teriflunomide","volume":"3","author":"Oh","year":"2013","journal-title":"Neurol Clin Pract"},{"key":"key20180107210043_b10-or-32-02-0627","first-page":"62","article-title":"Spotlight on teriflunomide","volume":"15","author":"Tallantyre","year":"2008","journal-title":"Int MS J"},{"key":"key20180107210043_b11-or-32-02-0627","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1517\/17425255.2013.800483","article-title":"Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis","volume":"9","author":"Wiese","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20180107210043_b12-or-32-02-0627","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40263-013-0080-z","article-title":"Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis","volume":"27","author":"Oh","year":"2013","journal-title":"CNS Drugs"},{"key":"key20180107210043_b13-or-32-02-0627","first-page":"177","article-title":"An update of teriflunomide for treatment of multiple sclerosis","volume":"9","author":"Oh","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"key20180107210043_b14-or-32-02-0627","doi-asserted-by":"crossref","first-page":"e71555","DOI":"10.1371\/journal.pone.0071555","article-title":"Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One"},{"key":"key20180107210043_b15-or-32-02-0627","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10495-011-0667-0","article-title":"Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes","volume":"17","author":"Hail","year":"2012","journal-title":"Apoptosis"},{"key":"key20180107210043_b16-or-32-02-0627","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.leu.2404922","article-title":"The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells","volume":"22","author":"Ringshausen","year":"2008","journal-title":"Leukemia"},{"key":"key20180107210043_b17-or-32-02-0627","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1593\/neo.10168","article-title":"Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention","volume":"12","author":"Hail","year":"2010","journal-title":"Neoplasia"},{"key":"key20180107210043_b18-or-32-02-0627","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/1078-0432.CCR-11-1049","article-title":"Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells","volume":"18","author":"Dietrich","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107210043_b19-or-32-02-0627","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/1535-7163.MCT-08-0664","article-title":"Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells","volume":"8","author":"Baumann","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"key20180107210043_b20-or-32-02-0627","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2174\/1381612013397177","article-title":"Rationally designed anti-mitotic agents with pro-apoptotic activity","volume":"7","author":"Uckun","year":"2001","journal-title":"Curr Pharm Des"},{"key":"key20180107210043_b21-or-32-02-0627","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature09882","article-title":"DHODH modulates transcriptional elongation in the neural crest and melanoma","volume":"471","author":"White","year":"2011","journal-title":"Nature"},{"key":"key20180107210043_b22-or-32-02-0627","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000341810","article-title":"Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro","volume":"97","author":"Somnay","year":"2013","journal-title":"Neuroendocrinology"},{"key":"key20180107210043_b23-or-32-02-0627","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"key20180107210043_b24-or-32-02-0627","doi-asserted-by":"crossref","first-page":"17617","DOI":"10.1074\/jbc.M502278200","article-title":"c-Myc suppresses p21WAF1\/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells","volume":"280","author":"Mukherjee","year":"2005","journal-title":"J Biol Chem"},{"key":"key20180107210043_b25-or-32-02-0627","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1073\/pnas.0710887105","article-title":"Tamoxifen-stimulated growth of breast cancer due to p21 loss","volume":"105","author":"Abukhdeir","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107210043_b26-or-32-02-0627","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0083-6729(05)71007-4","article-title":"Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer","volume":"71","author":"Riggins","year":"2005","journal-title":"Vitam Horm"},{"key":"key20180107210043_b27-or-32-02-0627","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1038\/onc.2012.335","article-title":"Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer","volume":"32","author":"Razandi","year":"2013","journal-title":"Oncogene"},{"key":"key20180107210043_b28-or-32-02-0627","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2013.06.006","article-title":"BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?","volume":"24","author":"Martin","year":"2013","journal-title":"Cancer Cell"},{"key":"key20180107210043_b29-or-32-02-0627","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1096\/fj.09-138305","article-title":"BCL2 and CASP8 regulation by NF-\u03baB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells","volume":"24","author":"Nehra","year":"2010","journal-title":"FASEB J"},{"key":"key20180107210043_b30-or-32-02-0627","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/1535-7163.MCT-09-1169","article-title":"IFN\u03b3 restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-\u03baB, BCL2 family members, and signaling to caspase-dependent apoptosis","volume":"9","author":"Ning","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"key20180107210043_b31-or-32-02-0627","doi-asserted-by":"crossref","first-page":"912102","DOI":"10.4061\/2011\/912102","article-title":"The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer","volume":"2011","author":"Schwartz","year":"2011","journal-title":"Int J Breast Cancer"},{"key":"key20180107210043_b32-or-32-02-0627","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-12-0269","article-title":"Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness","volume":"72","author":"Cook","year":"2012","journal-title":"Cancer Res"},{"key":"key20180107210043_b33-or-32-02-0627","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4161\/cc.24487","article-title":"Differences in regulation and function of E-cyclins in human cancer cells","volume":"12","author":"Geng","year":"2013","journal-title":"Cell Cycle"},{"key":"key20180107210043_b34-or-32-02-0627","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1535-7163.MCT-11-0963","article-title":"Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells","volume":"11","author":"Caldon","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"key20180107210043_b35-or-32-02-0627","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Cancer Discov"},{"key":"key20180107210043_b36-or-32-02-0627","doi-asserted-by":"crossref","first-page":"29.e1","DOI":"10.1016\/j.urolonc.2012.10.006","article-title":"Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy","volume":"32","author":"Lin","year":"2014","journal-title":"Urol Oncol"},{"key":"key20180107210043_b37-or-32-02-0627","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/molecules18010701","article-title":"Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7\/LCC2 and MCF-7\/LCC9","volume":"18","author":"Jiang","year":"2013","journal-title":"Molecules"},{"key":"key20180107210043_b38-or-32-02-0627","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-008-0058-6","article-title":"Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells","volume":"115","author":"Hiscox","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107210043_b39-or-32-02-0627","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4161\/cbt.12.10.17780","article-title":"Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells","volume":"12","author":"Martinez-Outschoorn","year":"2011","journal-title":"Cancer Biol Ther"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3249\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T16:00:56Z","timestamp":1515340856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,6,12]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.3892\/or.2014.3249"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3249","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,12]]}}}